CXCL8 and Splenomegaly: These data suggest that future therapies for MF should consider combining JAK1/2 inhibitors to reduce splenomegaly by using drugs targeting RAC1/2, to reduce malignant HSCs and/or the inflammatory milieu (IL-8 or TGF-β), and to reduce fibrosis and increase platelet counts.